574 reports of this reaction
5.5% of all BUROSUMAB reports
#3 most reported adverse reaction
BLOOD PHOSPHORUS DECREASED is the #3 most commonly reported adverse reaction for BUROSUMAB, manufactured by Kyowa Kirin, Inc.. There are 574 FDA adverse event reports linking BUROSUMAB to BLOOD PHOSPHORUS DECREASED. This represents approximately 5.5% of all 10,519 adverse event reports for this drug.
Patients taking BUROSUMAB who experience blood phosphorus decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD PHOSPHORUS DECREASED is moderately reported among BUROSUMAB users, representing a notable but not dominant share of adverse events.
In addition to blood phosphorus decreased, the following adverse reactions have been reported for BUROSUMAB:
BLOOD PHOSPHORUS DECREASED has been reported as an adverse event in 574 FDA reports for BUROSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD PHOSPHORUS DECREASED accounts for approximately 5.5% of all adverse event reports for BUROSUMAB, making it one of the most commonly reported side effect.
If you experience blood phosphorus decreased while taking BUROSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.